The DOI matches its Crossref record; 214 of the 214 references it cites were found in a registry or an index.
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)
Open accessAbstract
BACKGROUND The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. AIMS To review, from an Infectious Diseases perspective, the safety profile of agents targeting interleukins, immunoglobulins and complement factors and to suggest preventive recommendations. SOURCES Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family. CONTENT Patients receiving interleukin-1 (IL-1) -targeted (anakinra, canakinumab or rilonacept) or IL-5-targeted (mepolizumab) agents have a moderate risk of infection and no specific prevention strategies are recommended. The use of IL-6/IL-6 receptor-targeted agents (tocilizumab and siltuximab) is associated with a risk increase similar to that observed with anti-tumour necrosis factor-α agents. IL-12/23-targeted agents (ustekinumab) do not seem to pose a meaningful risk of infection, although screening for latent tuberculosis infection may be considered and antiviral prophylaxis should be given to hepatitis B surface antigen-positive patients. Therapy with IL-17-targeted agents (secukinumab, brodalumab and ixekizumab) may result in the development of mild-to-moderate mucocutaneous candidiasis. Pre-treatment screening for Strongyloides stercoralis and other geohelminths should be considered in patients who come from areas where these are endemic who are receiving IgE-targeted agents (omalizumab). C5-targeted agents (eculizumab) are associated with a markedly increased risk of infection due to encapsulated bacteria, particularly Neisseria spp. Meningococcal vaccination and chemoprophylaxis must be administered 2-4 weeks before initiating eculizumab. Patients with high-risk behaviours and their partners should also be screened for gonococcal infection. IMPLICATIONS Preventive strategies are particularly encouraged to minimize the occurrence of neisserial infection associated with eculizumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–214 of 214
Anti-IgE therapy for allergic bronchopulmonary aspergillosis
Homma, T., Kurokawa, M., Matsukura, S., Yamaguchi, M., & Adachi, M. (2013) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2013.10.003 · Cited by 27
A review of omalizumab for the management of severe asthma
Shih-Lung, C., & Lin, C. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s112208 · Cited by 27
Failla, V., & Nikkels, A. (2011) · Dermatology · doi:10.1159/000323736 · Cited by 26
Eculizumab for treatment of asthma
Smith, S. G., Watson, B. M., Clark, G., & Gauvreau, G. M. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.668517 · Cited by 24
Nagashima, T., Maruyama, A., Kamata, Y., & Minota, S. (2011) · Rheumatology International · doi:10.1007/s00296-011-2060-2 · Cited by 23
Secukinumab for treating plaque psoriasis
Rothstein, B. E., & Gottlieb, A. B. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1121986 · Cited by 23
del Río, C., Stephens, D. S., Knapp, J. S., RICE, R. J., & Schalla, W. O. (1989) · Journal of Clinical Microbiology · doi:10.1128/jcm.27.5.1045-1049.1989 · Cited by 21
Tsuboi, H., Tsujii, A., Nampei, A., et al. (2011) · Modern Rheumatology · doi:10.1007/s10165-011-0470-3 · Cited by 21
Pallares, D. E., Figueroa, J. E., Densen, P., Giclas, P. C., & Marshall, G. S. (1996) · The Journal of Pediatrics · doi:10.1016/s0022-3476(96)70436-5 · Cited by 17
Varicella zoster virus meningitis under ustekinumab because of plaque psoriasis
Stöllberger, C., & Finsterer, J. (2017) · The Journal of Dermatology · doi:10.1111/1346-8138.13755 · Cited by 16
Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade
Kahlenberg, J. M. (2016) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000266 · Cited by 13
Webb, B. J., Healy, R., Child, B., Majers, J., Anand, S., & Gouw, L. G. (2016) · Transplant Infectious Disease · doi:10.1111/tid.12517 · Cited by 12
Necrotizing Fasciitis in Paroxysmal Nocturnal Hemoglobinuria
Patır, P., Işik, Y., Türk, Y., Uğur, M. C., Ceylan, C., Görgün, G., Mete, N., Saydam, G., & Şahin, F. (2015) · Case Reports in Hematology · doi:10.1155/2015/908087 · Cited by 9
Mepolizumab for the reduction of exacerbations in severe eosinophilic asthma
RUSSELL, R. J., & Brightling, C. E. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1176532 · Cited by 9
Cited by
Eosinophil responses during COVID-19 infections and coronavirus vaccination
Lindsley, A. W., Schwartz, J. T., & Rothenberg, M. E. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.021 · Cited by 354
The Diagnosis and Treatment of Tuberculosis
Suárez, I., Fünger, S. M., Kröger, S., Rademacher, J., Fätkenheuer, G., & Rybniker, J. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0729 · Cited by 264
Metadata
- Authors
- Winthrop, K. L., Mariette, X., Silva, J. T., Benamu, E., Calabrese, L. H., Dumusc, A., Smolen, J. S., Aguado, J. M., & Fernández-Ruiz, M.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 24
- Pages
- S21-S40
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W2785674074
- Cited by
- 259
- References
- 214
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.